NCT02408861 2026-01-21Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 1 Terminated79 enrolled 24 charts
NCT03425331 2026-01-08Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCDana-Farber Cancer InstitutePhase 2 Terminated5 enrolled 13 charts